We just received a grant to study the very rare, but uniformly fatal disease called Progeria (or Hutchinson-Gilford Progeria Syndrome). This is a rare, fatal genetic condition characterized by accelerated aging in children. Our small competitive grant is from the Progeria Research Foundation.
January 29th in San Diego, CA.
The Johns Hopkins Department of Medicine just announced the transfer of my primary appointment to their Division of Clinical Pharmacology, and my change from Acting Director to Director of the Cullman Chemoprotection Center.
Their blog post highlights our interest in inclusive research collaborations across the entire JHU community (which includes the Arts and Science campus and the schools of Public Health, Nursing, Engineering, Education, and Business).
The center occupies space in both the Rangos and Wood Basic Science Buildings. In addition to basic research on the development and application of plant-based compounds for the prevention and treatment of chronic disease, the Cullman Center collaborates on a range of clinical studies both domestically and internationally.
November 20, 2015, Tokyo Japan